viewCellmid Limited

Cellmid builds IP for midkine portfolio with new patents

The company's patent portfolio comprises 60 patents and applications in 13 patent families.

folder labeled Patents
Detecting midkine in adults can be used as an indicator for detecting diseases

Cellmid Ltd (ASX:CDY) has strengthened and secured the intellectual property (IP) in its midkine antibodies portfolio after being granted a US patent and advancing a European patent.

The US Patent Office granted the patent application entitled "Antibody recognizing N-domain of midkine".

In addition, Cellmid received a ‘Notification of Intention to Grant’ from the European Patent Office for the corresponding patent in key European territories.

READ: Cellmid launches évolis® Professional products in 17 store locations across the US

The newly granted midkine antibody patents and allied patent families underpin the company’s dominant IP position over the use of therapeutic midkine antibodies for the treatment of diseases.

These diseases arise from cancer, chronic inflammation, surgical adhesions and functional disorders in T-regulatory cells associated with autoimmune diseases.

Midkine is an important early marker for diagnosing diseases

Midkine is a growth factor that is highly expressed during embryonic development.

It modulates many important biological interactions such as cell growth that are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing.

Midkine is barely detectable in healthy adults midkine expression is often evident very early in disease onset, even before any apparent physical symptoms.

Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases.

Finally, midkine is only evident in a disease context, and targeting midkine is not expected to harm normal healthy tissues.

Quick facts: Cellmid Limited

Price: 0.097 AUD

Market: ASX
Market Cap: $12.15 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...


Cellmid Limited to supply rapid diagnostic tests to help in new pandemic

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...

on 30/3/20

2 min read